Filter By Category
Archives
Share on -
DUTACATIB
Generic Name: DUTACATIB
ABSTRACT -
Dutacatib is an investigational cathepsin K inhibitor studied for osteoporosis and cancer-induced bone disease. It reversibly inhibits cathepsin K-mediated collagen degradation.
DOSAGE -
No approved dosage. Oral dosing followed dose-escalation or preclinical/clinical study protocol.
SIDE EEFECTS -
- Gastrointestinal upset
- Headache
- Fatigue
- Skin or rash events
- Laboratory abnormalities
ALLERGIC REACTIONS -
(These symptoms may indicate an allergic reaction and require medical attention.)
- Rash or pruritus
- Urticaria
- Facial swelling
- Anaphylaxis (rare)
DRUG INTERACTIONS-
- CYP-mediated interactions should be assessed in protocols
- Other bone-modifying agents may have additive skeletal effects
- Concomitant hepatotoxic drugs require caution
PREAUTONS–
- Investigational compound
- Monitor hepatic and renal laboratory parameters
- Assess bone-related endpoints and safety markers
WARNINGS –
- Safety and efficacy not established
- Avoid use outside research protocols
Share on -
. Developed by